Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03233646 · ClinicalTrials.gov registry record
Retinal Imaging in Neurodegenerative Disease
A clinical trial of Multiple Sclerosis and Mild Cognitive Impairment, sponsored by Duke University.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT03233646: Recruiting study of Multiple Sclerosis and Mild Cognitive Impairment, sponsored by Duke University.
NCT03233646 is a study of Multiple Sclerosis and Mild Cognitive Impairment that is actively recruiting participants, run by Duke University. The registered enrollment target is 2,000 participants, above the 579-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (245% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03233646, a study of Multiple Sclerosis and Mild Cognitive Impairment, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.
Primary Outcome
Ganglion cell inner plexiform layer thickness as measured on optical coherence tomography scan of macula
Conditions Studied
Interventions
- DEVICE Retinal and Choroidal Imaging
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2017-07-20 |
| Est. Completion | 2026-12-31 |
What NCT03233646 shows while recruiting
NCT03233646 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 579-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (245% higher).
The record links to 10 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Retinal and Choroidal Imaging is the first listed.
NCT03233646 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03233646 about?
NCT03233646 is a clinical study titled "Retinal Imaging in Neurodegenerative Disease". This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mil...
What is the current status of trial NCT03233646?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2017-07-20. Estimated completion is 2026-12-31.
What conditions does trial NCT03233646 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Mild Cognitive Impairment, Traumatic Brain Injury, Parkinson's Disease, Alzheimers Disease.
What interventions are being tested in trial NCT03233646?
The interventions under investigation include: Retinal and Choroidal Imaging (DEVICE).
Who is sponsoring clinical trial NCT03233646?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03233646 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03233646's enrollment target sits among peer trials
2,000 15th of 315 higher than 299 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI